Skip to main content
. Author manuscript; available in PMC: 2020 Apr 24.
Published in final edited form as: J Am Chem Soc. 2019 Apr 15;141(16):6453–6457. doi: 10.1021/jacs.8b13681

Figure 1.

Figure 1.

Summary of the NCI-60 human tumor cell lines screen. AP-1 shows superior activity compared to arsenic trioxide in all 9 indications tested; it also shows higher potency than cisplatin in breast, leukemia, colon, and CNS. Numbers in parentheses represent number of cell lines tested for each indication (Figures S4–S6).